ACAM2000

Vaccine

Approvedregulatory verdict

Evidence outlook

Approved: Smallpox and Mpox

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Weak signal

Also approved (4)
SA
  • Prevention of smallpox and mpox in individuals at high risk
Product first approved 2026biospace.com
CA
  • Smallpox vaccine (Extraordinary Use New Drug Submission; Notice of Compliance)
Product first approved 2023dhpp.hpfb-dgpsa.ca
SG
  • Active immunization for the prevention of smallpox disease in individuals at high risk; indication expanded to mpox on 2026-04-30
Product first approved 2009biospace.com
AU
  • Smallpox vaccine (licensed for smallpox)
biospace.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (1)
Other / comorbidity
Phase 2 (2)
Other / comorbidity
NCT00053495 · Emergent BioSolutions
2003-01 – 2003-11 · Smallpox
What this study did
NCT00053482 · Emergent BioSolutions
2003-01 – 2003-10 · Smallpox
What this study did
Phase 4 (1)
Other / comorbidity
NCT02443623 · Emergent BioSolutions
2015-09 – 2021-08 · Smallpox Vaccine Adverse Reaction
What this study did
Appears in other studies (1)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Other / comorbidity
NCT01913353 · Bavarian Nordic
2015-03 – 2017-08 · 18-42 Year Old Healthy Vaccinia-naïve Subjects
What this study did

Competitive landscape

No competitors sharing a mechanism or indication in the current universe.

Upcoming events

No upcoming readouts on record for this asset.